哮喘中的气道微生物组
本文综述气道微生物组在哮喘发生、严重程度和炎症内型中的作用。气道微生物组失调与哮喘发生、疾病严重程度和炎症内型相关,但因果方向尚不明确。嗜血杆菌、莫拉菌以及鼻病毒和呼吸道合胞病毒与儿童哮喘发生相关。嗜酸性炎症患者微生物多样性与健康人相似,中性粒细胞炎症与微生物多样性降低、细菌负荷增高及病原体主导的微生物组谱相关。
要点
- 气道微生物组失调与哮喘发生、严重程度和炎症内型相关。
- 中性粒细胞炎症与微生物多样性降低和细菌负荷增高相关。
- 嗜酸性炎症微生物多样性与健康人相似。
核心结论
- 气道微生物组失调与哮喘发生、疾病严重程度和炎症内型相关,但失调驱动炎症还是炎症导致失调尚不明确。
研究设计与样本
- 综述,总结气道微生物组在哮喘中的研究证据,指出多数研究关注细菌组分,需进一步研究病毒组和真菌组。
主要发现
- 嗜血杆菌和莫拉菌与鼻病毒和呼吸道合胞病毒与儿童哮喘发生相关。
- 已确诊哮喘中,气道微生物组失调与严重程度和急性加重风险相关。
- 不同炎症内型有不同气道微生物组谱。
- 嗜酸性炎症患者微生物多样性与健康个体相似。
- 中性粒细胞炎症与微生物多样性降低、细菌负荷增高和病原体主导的微生物组谱相关。
临床怎么用
- 理解微生物组失调在中性粒细胞炎症哮喘中的作用,该型目前对抗2型生物制剂难治。
- 需将微生物组数据与蛋白质组学等其他组学方法整合以理解其作用。
- 抗生素、益生菌、单克隆抗体和饮食理论上可靶向气道和肠道微生物组治疗哮喘。
局限性
- 多数微生物组研究调查细菌组分,病毒组和真菌组作用需进一步研究。
- 微生物组失调与炎症的因果关系尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TOPIC IMPORTANCE: Asthma is a heterogenous airways disease characterized by variable airflow limitation, airway inflammation, and bronchial hyperresponsiveness. Evidence suggests that the airway microbiome plays an important role in asthma pathophysiologic characteristics. Most microbiome studies have investigated the bacterial constituents of the microbiome, and further studies are needed to investigate the role of the airway virome and mycobiome in asthma. REVIEW FINDINGS: Airway microbiome dysbiosis is associated with asthma development, disease severity, and inflammatory endotypes. However, it remains unclear whether dysbiosis drives inflammation or is a result of inflammation. Haemophilus and Moraxella alongside rhinovirus and respiratory syncytial virus have been shown to be associated with the development of asthma in children. In established asthma, airway microbiome dysbiosis is associated with severity and risk of exacerbation. Distinct airway microbiome profiles are observed for the different inflammatory endotypes. Patients with asthma and eosinophilic inflammation have higher microbial diversity similar to that of healthy individuals, whereas neutrophilic inflammation is associated with reduced microbial diversity, higher bacterial load, and a pathogen-dominated microbiome profile, suggesting an important role for dysbiosis in asthma that currently is refractory to antitype 2 biologic therapy. SUMMARY: To understand the role of the microbiome in asthma, microbiome data must be integrated with other so-called omic approaches such as proteomics. Recent studies have used a multiomic approach to investigate the microbiome and host interaction as well as identifying asthma endotypes and potential therapeutic targets. Antibiotics, probiotics, monoclonal antibodies, and diet theoretically could be used to target the airway and gut microbiome therapeutically in asthma.
引用
- Richardson H, Pollock J, Chan R, et al. The Airway Microbiome in Asthma. Chest. 2026. PMID: 42674280. doi:10.1016/j.chest.2026.08.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。